H W Cohen1, S Madhavan, M H Alderman. 1. Department of Epidemiology and Social Medicine, Albert Einstein College of Medicine, Bronx, New York 10461, USA. hicohen@aecom.yu.edu
Abstract
OBJECTIVE: To determine the relationship of moderately high and low concentrations of serum potassium with cardiovascular disease events among treated hypertensive patients. DESIGN: An observational cohort study with prospectively collected data. SETTING: A worksite treatment program for mild hypertension. PATIENTS: All program participants with baseline and at least one annual follow-up measure of serum potassium; 7,653 individuals with 6.7 years mean follow-up met these criteria. MAIN OUTCOME MEASURES: Outcome events were admissions to hospital because of cardiovascular disease, and deaths. The research question regarding serum potassium categories was formulated after data collection. The serum potassium concentration (mean +/- 2SD) of the study population was used to define low (3.0-3.5 mmol/l), high (5.1-5.9 mmol/l) and middle (3.6-5.0 mmol/l) categories. RESULTS: Individuals with low (n = 146) and high (n = 226) serum potassium had significantly greater risk for cardiovascular disease events than those in the middle category (n = 7,281). Multivariate adjusted hazard ratios from Cox models were 2.6 [95% confidence intervals (CI) 1.5-4.4] for the low potassium group and 1.7 (95% CI 1.0-2.7) for the high potassium group, with the middle group as reference. Among 1,679 individuals who regularly took diuretics, hazard ratios were 4.3 (95% CI 2.4-7.9) for the low potassium group and 6.7 (95% CI 2.8-15.9) for the high group. Neither low nor high potassium was significantly associated with outcome events for those not regularly using diuretics. CONCLUSIONS: These data confirm an association of mild hypokalemia with increased cardiovascular events among diuretic-treated hypertensive patients. In addition, we have found a similar increased cardiovascular risk associated with modest hyperkalemia among these patients. Whether modification of these serum potassium concentrations would alter that risk remains to be determined.
OBJECTIVE: To determine the relationship of moderately high and low concentrations of serum potassium with cardiovascular disease events among treated hypertensivepatients. DESIGN: An observational cohort study with prospectively collected data. SETTING: A worksite treatment program for mild hypertension. PATIENTS: All program participants with baseline and at least one annual follow-up measure of serum potassium; 7,653 individuals with 6.7 years mean follow-up met these criteria. MAIN OUTCOME MEASURES: Outcome events were admissions to hospital because of cardiovascular disease, and deaths. The research question regarding serum potassium categories was formulated after data collection. The serum potassium concentration (mean +/- 2SD) of the study population was used to define low (3.0-3.5 mmol/l), high (5.1-5.9 mmol/l) and middle (3.6-5.0 mmol/l) categories. RESULTS: Individuals with low (n = 146) and high (n = 226) serum potassium had significantly greater risk for cardiovascular disease events than those in the middle category (n = 7,281). Multivariate adjusted hazard ratios from Cox models were 2.6 [95% confidence intervals (CI) 1.5-4.4] for the low potassium group and 1.7 (95% CI 1.0-2.7) for the high potassium group, with the middle group as reference. Among 1,679 individuals who regularly took diuretics, hazard ratios were 4.3 (95% CI 2.4-7.9) for the low potassium group and 6.7 (95% CI 2.8-15.9) for the high group. Neither low nor high potassium was significantly associated with outcome events for those not regularly using diuretics. CONCLUSIONS: These data confirm an association of mild hypokalemia with increased cardiovascular events among diuretic-treated hypertensivepatients. In addition, we have found a similar increased cardiovascular risk associated with modest hyperkalemia among these patients. Whether modification of these serum potassium concentrations would alter that risk remains to be determined.
Authors: Michael H Alderman; Linda B Piller; Charles E Ford; Jeffrey L Probstfield; Suzanne Oparil; William C Cushman; Paula T Einhorn; Stanley S Franklin; Vasilios Papademetriou; Stephen T Ong; John H Eckfeldt; Curt D Furberg; David A Calhoun; Barry R Davis Journal: Hypertension Date: 2012-03-19 Impact factor: 10.190
Authors: Cinzia Cortesi; Sebastiano A G Lava; Alberto Bettinelli; Fabiana Tammaro; Olivier Giannini; Maria Caiata-Zufferey; Mario G Bianchetti Journal: Pediatr Nephrol Date: 2010-06-13 Impact factor: 3.714
Authors: Marguerite R Irvin; Colleen M Sitlani; Raymond Noordam; Christie L Avery; Joshua C Bis; James S Floyd; Jin Li; Nita A Limdi; Vinodh Srinivasasainagendra; James Stewart; Renée de Mutsert; Dennis O Mook-Kanamori; Leonard Lipovich; Erica L Kleinbrink; Albert Smith; Traci M Bartz; Eric A Whitsel; Andre G Uitterlinden; Kerri L Wiggins; James G Wilson; Degui Zhi; Bruno H Stricker; Jerome I Rotter; Donna K Arnett; Bruce M Psaty; Leslie A Lange Journal: Pharmacogenomics J Date: 2018-06-01 Impact factor: 3.245
Authors: Charat Thongprayoon; Wisit Cheungpasitporn; Panupong Hansrivijit; Michael A Mao; Juan Medaura; Tarun Bathini; Api Chewcharat; Stephen B Erickson Journal: Medicines (Basel) Date: 2019-12-30